Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Vitamin C - a new player in regulation of the cancer epigenome

Research output: Contribution to journalReviewResearchpeer-review

  1. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)

    Research output: Contribution to journalReviewResearchpeer-review

  2. Multiple endocrine neoplasia type 2: A reveiw

    Research output: Contribution to journalReviewResearchpeer-review

  1. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Structural aberrations are associated with poor survival in patients with clonal cytopenia of undetermined significance

    Research output: Contribution to journalLetterResearchpeer-review

  3. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Over the past few years it has become clear that vitamin C, as a provider of reduced iron, is an essential factor for the function of epigenetic regulators that initiate the demethylation of DNA and histones. Vitamin C deficiency is rare in the general population, but is frequently observed in patients with cancer. Genes encoding epigenetic regulators are often mutated in cancer, underscoring their central roles in carcinogenesis. In hematological cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), drugs that reverse epigenetic aberrations are now the standard of care. Recent in vitro studies suggest that vitamin C at physiological concentrations, combined with hypomethylating agents may act synergistically to cause DNA demethylation through active and passive mechanisms, respectively. Additionally, several recent studies have renewed interest in the use of pharmacological doses of vitamin C injected intravenously to selectively kill tumour cells. This review will focus on the potential of vitamin C to optimize the outcome of epigenetic therapy in cancer patients and alternatively to act as a therapeutic at high doses.

Original languageEnglish
JournalSeminars in Cancer Biology
Pages (from-to)59-67
ISSN1044-579X
DOIs
Publication statusPublished - Aug 2018

    Research areas

  • Journal Article, Review

ID: 52055993